Keyword: Hikma Pharmaceuticals
Acorda faces the prospect of generic competition on its primary revenue source, Ampyra, after an appeals court's decision.
Alvogen and Hikma are locked in a legal battle over the use of their drugs in a planned Nevada execution.
Hikma is looking to ease the U.S. shortage of hydromorphone as the FDA gave its OK to Terumo BCT to shore up short supplies of anticoagulant solution.
Based in Jordan, Hikma has substantial presence in the MENA region, which contributed 33% of its total revenue in 2017.
Joining other drug companies announcing slim-down efforts in recent months, Astellas is shedding 600 jobs in Japan in R&D and sales and marketing.
Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.
Hikma Pharmaceuticals is changing up more than just its CEO. It's rebranded, with a modern logo and visual identity.
Hikma has already cut 200 jobs since picking up generics business Roxane Labs from Boehringer Ingelheim. But more layoffs are coming.
GlaxoSmithKline just keeps racking up the victories in the generic Advair department, this time with a yearslong delay to Hikma's copy.
Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as the new CEO of Jordan’s Hikma Pharmaceuticals.